



IBA launches VISICOIL™ designed for safer and easier implantation in Interventional Radiology

New VISICOIL fiducial marker pre-loaded in 21g & 22g thin needle to aid in percutaneous / transthoracic placement. More patients to benefit from pinpoint set-up accuracy in Radiation Therapy.

Atlanta, Georgia, September 19th, 2013 – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, announces the launch of an extension to the VISICOIL product line at the annual ASTRO congress of the American Society for Radiation Oncology. This new design incorporates kV x-ray imaging compliant VISICOIL Linear Markers pre-loaded in 21g and 22g needles that are almost half the size of needles typically used for placement of gold seeds.

Compared to typical gold seeds, this new design enhances the ability of Interventional Radiology to safely and efficiently implant VISICOIL markers, which subsequently supports radiation oncologists in highly precise patient setup and dose delivery during radiation therapy.

This new solution offers clinical benefits associated with smaller needles, such as increased patient safety and improved patient comfort. IBA's patented VISICOIL linear fiducial markers are an important component in the effort to increase targeting accuracy in Radiation Therapy applications such as SBRT, IGRT, IMRT, CyberKnife® and Proton Therapy.

"We are very excited to offer this new solution. Patients now have an option for a safer and less invasive procedure through Interventional Radiology", said Kevin Reynolds, VISICOIL Product Manager at IBA. "It's great to see the high level of interest from Radiation Oncologists and Interventional Radiologists in the new smaller 15cm 21 gauge and 22 gauge needles ideal for CT guided placement."

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room systems.

IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

IBA employs more than 1,200 people worldwide and is listed on Euronext Brussels, (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB), more information can be found at: www.iba-worldwide.com

About VISICOIL™

VISICOIL is manufactured by RadioMed Corporation which was founded in 1997 as a private corporation and became part of IBA in 2003. VISICOIL is a patented (US Patent 8,027,712) helically wound gold coil available in



various diameters and lengths to aid in the treatment of a range of radiation therapy techniques that target the prostate, lung, liver, pancreas, breast, and various other organs.

The clinical success of focused, dose-delivery procedures such as image guided radiation therapy (IGRT) and conformal radiation therapy (CRT) is based on the accuracy of target identification and precise patient positioning. VISICOIL's flexible coiled markers allow for accurate tumor localization, using a variety of visualization techniques. VISICOIL is a general-purpose implanted fiducial marker. The marker is indicated for use to radiographically mark soft tissue for future therapeutic procedures, per US FDA cleared 510(K). Guided by VISICOIL, over 50,000 cancer patients worldwide have been treated with radiation therapy more safely and more accurately. VISICOIL is manufactured in various diameters and lengths by RadioMed Corporation, an IBA company. For more information about VISICOIL, please visit www.VISICOIL.com.

Media Contact:

Kevin Reynolds
VISICOIL Product Manager
IBA America - Bartlett, TN.
Tel: (901) 432-7202
Kevin.reynolds@iba-group.com

Press release | **September 19, 2013**

###